We are pleased to announce the addition of two new conditions to our TreatGx medication decision support system. Alzheimer’s Disease and Insomnia can now be accessed by all TreatGx users. The Alzheimer’s algorithm provides treatment options for adults with mild, moderate, or severe Alzheimer’s disease, and includes guidance on medication titration and switching. Treatment options and dosing are based on the most up-to-date...
The GenXys algorithm for Smoking Cessation has been updated and the new version is available to all TreatGx users. To continue to provide effective medication options and strategies for smoking cessation, we reviewed and incorporated information from recent guidelines and papers. These include the 2018 NICE guideline [1] and the 2018 American College of Cardiology expert consensus decision pathway [2]. We also included evidence from a recent Cochrane review on the use of different doses, durations...
Some governing bodies have temporarily changed certain regulations so that healthcare providers can do as much as possible to deliver high-quality care virtually. Some areas of care become more challenging in a virtual environment, but with the right support tools in place, these challenges can...
All TreatGx users now have access to the updated Epilepsy and Rheumatoid Arthritis treatment algorithms. The Epilepsy update includes comprehensive treatment recommendations for specific types of epilepsy from the latest international guidelines, including the National Institute for Health and Care Excellence [1], Scottish Intercollegiate Guidelines Network...
We are pleased to announce the addition of a new condition to our TreatGx website! Crohn’s disease is available for access to all TreatGx users. This algorithm provides medication treatment options for adults with mild, moderate and severe disease as well as for maintenance of...
All TreatGx users have access to the updated Bipolar I Disorder treatment algorithm and the Acute Exacerbation of COPD treatment algorithm. These comprehensive updates include many exciting enhancements that will help health care providers select the safest and most effective medications with their patients. All...
As leaders in making pharmacogenetics clinically relevant and useful in primary care, we ensure that we keep up to date with research. Your genes have not changed, but new research evidence has allowed us to interpret them more precisely. This new interpretation may impact some...
In February 2020, the FDA released a Table of Pharmacogenetic Associations which includes a list of medications for which they believe there is sufficient evidence to suggest an association between a genetic variant and the metabolism or therapeutic effect of a medication. In order to...
In today’s article, our Chief Scientific Officer, Prof. Martin Dawes will discuss the role of pharmacogenetics in treating depression. You’ll also learn about a solution that enables the use of evidence-based pharmacogenetics at the point of care....
In this interview with our Algorithm Team Manager, Andrea Paterson, she talks about the exciting updates on our TreatGx software, and how to use it to select the best medication options for patients with depression. ...
